U.S. authorizes Sobi's drug to treat COVID-19 in high-risk patients

U.S. authorizes Sobi's drug to treat COVID-19 in high-risk patients Sobi North America, a unit of Swedish Orphan Biovitrum AB , said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug for treatment of high-risk hospitalized COVID-19 patients. Reuters Reuters

...

The drug, already approved in the European Union for treating COVID, has been authorized in the United States to treat patients with pneumonia who require oxygen support and those at risk of developing severe respiratory failure.

...